Role of anti-Siglec-15 in non-small cell lung cancer
Received:June 21, 2022  
View Full Text  View/Add Comment  Download reader
DOI:10. 3969 / j.issn.1671-7856. 2023. 01. 019
KeyWord:ICIs; Siglec-15; NSCLC
李延康 包头市中心医院内蒙古医科大学包头临床医学院心胸外科,内蒙古 包头
贺钢枫 包头市中心医院内蒙古医科大学包头临床医学院心胸外科,内蒙古 包头
Hits: 390
Download times: 165
      As a newly discovered ICI, Siglec-15 is widely expressed in various tumor cell types, and PD-1/ PD-L1 expressions is mutually exclusive. Siglec-15 may be a new therapeutic target for PD-1/ PD-L1 as a treatment option for patients who do not respond to therapy. This review discusses the recent research of the characteristic pathways of Siglec- 15, its involvement in immune regulation mechanisms, and its tumor-related expression. Clinical application of an anti- Siglec-15 antibody was analyzed, and the therapeutic prospect of Siglec-15 for NSCLC treatment is discussed.
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes";,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h;,"",win); } &et=A31A26E85506B300368E4C0C01176008A608F2D9A3D93722C855570B86DE59B0A15752AC55346EFDEB902CB20EC4F58B72D64F2A682BE635&pcid=&cid=&jid=&yid=BA1E75DF0B7E0EB2&aid=&vid=&iid=CA4FD0336C81A37A&sid=3986B25773CB6C30&eid=856C2E13D1000DB7&fileno=202301019&flag=1&is_more=0"> var my_pcid=""; var my_cid=""; var my_jid=""; var my_yid="BA1E75DF0B7E0EB2"; var my_aid="";